Biomarkers and the post-thrombotic syndrome: A systematic review of biomarkers associated with the occurrence of the post-thrombotic syndrome after lower extremity deep venous thrombosis
Restricted accessReview articleFirst published online October, 2023
Biomarkers and the post-thrombotic syndrome: A systematic review of biomarkers associated with the occurrence of the post-thrombotic syndrome after lower extremity deep venous thrombosis
Post-thrombotic syndrome (PTS) is a frequent chronic complication of deep venous thrombosis (DVT). Biomarkers are potentially valuable clinical tools for handling PTS. The purpose of this review was to examine which biomarkers are associated with the development of PTS in adults with lower extremity DVT.
Methods
We performed a systematic review of all English language prospective studies of biomarkers and PTS published in PubMed and EMBASE. Studies were included if diagnosing DVT by diagnostic imaging and assessing PTS by clinical scales, for example, the Villalta scale. Biomarkers of thrombophilia and pathological clot properties were not assessed. Data was reported qualitatively.
Results
15 prospective studies were included. Studies varied widely in study design and methods of data analysis. Forty-six different biomarkers were examined, with seven being measured in two or more studies. The most frequently studied biomarkers were D-dimer, CRP, and IL-6. Associations between PTS and D-dimer were predominantly significant, while results on CRP and IL-6 were inconsistent. ICAM-1 was consistently associated with PTS in all studies and at all timepoints. IL-10 was significantly related to PTS development in the largest study and at all time points. Adiponectin, tPA, HRG and TAFI, MMP-1 and -8, and TIMP-1 and -2 were significantly associated with PTS in single studies.
Conclusion
(1) Further research on biomarkers and PTS is clearly warranted. (2) Significant differences in study designs made it difficult to draw reliable conclusions regarding individual biomarkers. We suggest the implementation of a standardized framework for the study of biomarkers and PTS, to make comparison of future studies more feasible. (3) D-dimer, ICAM-1, IL-10, MMP-1 and 8, TIMP-1, TIMP-2, and adiponectin are clinical biomarkers of particular interest to include in future studies of PTS. Large scale systemic quantitative proteomic analyses of DVT patients could help identify novel biomarkers of interest in PTS-patients.
KhanFTritschlerTKahnSR, et al.Venous thromboembolism. Lancet2021; 398: 64–77.
2.
WellsPSIhaddadeneRReillyA, et al.Diagnosis of venous thromboembolism: 20 years of progress. Ann Intern Med2018; 168: 131–140.
3.
ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost2014; 12: 1580–1590.
4.
TagalakisVPatenaudeVKahnSR, et al.Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med2013; 126: 832. e13–21.
5.
RabinovichACohenJMCushmanM, et al.Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis. J Vasc Surg Venous Lymphat Disord2015; 3: 347–353.
6.
KahnSRComerotaAJCushmanM, et al.The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation2014; 130: 1636–1661.
7.
KahnSR. The post thrombotic syndrome. Thromb Res2011; 127(Suppl 3): S89–S92.
8.
KahnSR. How i treat postthrombotic syndrome. Blood2009; 114: 4624–4631.
9.
PrandoniPKahnSR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol2009; 145: 286–295.
10.
KahnSRShrierIJulianJA, et al.Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med2008; 149: 698–707.
11.
SilvaJCConstâncioVLimaP, et al.Determinants of quality of life in patients with post-thrombotic syndrome. Ann Vasc Surg2022; 85: 253–261.
12.
KahnSRShbakloHLampingDL, et al.Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost2008; 6: 1105–1112.
13.
KahnSRHirschAShrierI. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med2002; 162: 1144–1148.
14.
AshraniAAHeitJA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis2009; 28: 465–476.
15.
MacDougallDAFeliuALBoccuzziSJ, et al.Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm2006; 63: S5–S15.
16.
RabinovichAKahnSR. The postthrombotic syndrome: current evidence and future challenges. J Thromb Haemost2017; 15: 230–241.
17.
VazquezSRKahnSR. Advances in the diagnosis and management of postthrombotic syndrome. Best Pract Res Clin Haematol2012; 25: 391–402.
18.
HenkePKComerotaAJ. An update on etiology, prevention, and therapy of postthrombotic syndrome. J Vasc Surg2011; 53: 500–509.
19.
WakefieldTWHenkePK. The role of inflammation in early and late venous thrombosis: are there clinical implications?Semin Vasc Surg2005; 18: 118–129.
20.
WojcikBMWrobleskiSKHawleyAE, et al.Interleukin-6: a potential target for post-thrombotic syndrome. Ann Vasc Surg2011; 25: 229–239.
21.
MukhopadhyaySJohnsonTADuruN, et al.Fibrinolysis and inflammation in venous thrombus resolution. Front Immunol2019; 10: 1348.
22.
Roumen-KlappeEMden HeijerMvan UumSHM, et al.Inflammatory response in the acute phase of deep vein thrombosis. J Vasc Surg2002; 35: 701–706.
RabinovichACohenJMKahnSR. Predictive value of markers of inflammation in the postthrombotic syndrome: a systematic review: inflammatory biomarkers and PTS. Thromb Res2015; 136: 289–297.
26.
BoumanACSmitsJJMTen CateH, et al.Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome. J Thromb Haemost2012; 10: 1532–1538.
27.
ShbakloHHolcroftCAKahnSR. Levels of inflammatory markers and the development of the post-thrombotic syndrome. Thromb Haemost2009; 101: 505–512.
28.
DronkersCEAMolGCMarazitiG, et al.Predicting post-thrombotic syndrome with ultrasonographic follow-up after deep vein thrombosis: a systematic review and meta-analysis. Thromb Haemost2018; 118: 1428–1438.
29.
VillaltaSBagatellaPPiccioliA, et al.Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome. Haemostasis1994; 24: 158a.
30.
SoosainathanAMooreHMGohelMS, et al.Scoring systems for the post-thrombotic syndrome. J Vasc Surg2013; 57: 254–261.
31.
KahnSR. Measurement properties of the Villalta scale to define and classify the severity of the post-thrombotic syndrome. J Thromb Haemost2009; 7: 884–888.
32.
KahnSRPartschHVedanthamS, et al.Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost2009; 7: 879–883.
33.
NgSRodgerMAGhanimaW, et al.External validation of the patient-reported Villalta scale for the diagnosis of postthrombotic syndrome. Thromb Haemost2022; 122: 1379–1383.
34.
KahnSRGinsbergJS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med2004; 164: 17–26.
35.
KahnSRShapiroSWellsPS, et al.Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet2014; 383: 880–888.
36.
JinYWYeHLiFY, et al.Compression stockings for prevention of postthrombotic syndrome: a systematic review and meta-analysis. Vasc Endovascular Surg2016; 50: 328–334.
37.
AzirarSAppelenDPrinsMH, et al.Compression therapy for treating post-thrombotic syndrome. Cochrane Database Syst Rev2019; 9: CD004177.
38.
BurgstallerJMSteurerJHeldU, et al.Efficacy of compression stockings in preventing post-thrombotic syndrome in patients with deep venous thrombosis: a systematic review and metaanalysis. Vasa2016; 45: 141–147.
39.
SkervinALThaparAFranchiniAJ, et al.Systematic review and meta-analysis of utility of graduated compression stockings in prevention of post-thrombotic syndrome. Eur J Vasc Endovasc Surg2016; 51: 838–845.
40.
AppelenDvan LooEPrinsMH, et al.Compression therapy for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev2017; 9: CD004174.
41.
NottenPTen Cate-HoekAJArnoldussenCWKP, et al.Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. Lancet Haematol2020; 7: e40–e49.
42.
BroderickCWatsonLArmonMP. Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb. Cochrane Database Syst Rev2021; 1: CD002783.
43.
AshrafiMAhmadSBAntoniouSA, et al.Treatment strategies for proximal deep vein thrombosis: a network meta-analysis of randomised controlled trials. Eur J Vasc Endovasc Surg2022; 63: 323–334.
DeeksJJDinnesJD’AmicoR, et al.Evaluating non-randomised intervention studies. Health Technol Assess2003; 7: 1–173. iii–x.
46.
RabinovichACohenJMKahnSR. Predictive value of markers of inflammation in the postthrombotic syndrome: a systematic review: inflammatory biomarkers and PTS. Thromb Res2015; 136: 289–297.
47.
RabinovichACohenJMKahnSR. The predictive value of markers of fibrinolysis and endothelial dysfunction in the post thrombotic syndrome. A systematic review. Thromb Haemost2014; 111: 1031–1040.
48.
SiudutJNatorskaJSonM, et al.Increased levels of histidine-rich glycoprotein are associated with the development of post-thrombotic syndrome. Sci Rep2020; 10: 14419.
49.
FranciscisS deGallelliLAmatoB, et al.Plasma MMP and TIMP evaluation in patients with deep venous thrombosis: could they have a predictive role in the development of post-thrombotic syndrome?Int Wound J2016; 13: 1237–1245.
50.
RobertsLNPatelRKChitongoPB, et al.Presenting D-dimer and early symptom severity are independent predictors for post-thrombotic syndrome following a first deep vein thrombosis. Br J Haematol2013; 160: 817–824.
51.
IdingAFJKremersBMMNagyM, et al.Translational insights into mechanisms underlying residual venous obstruction and the role of factor XI, P-selectin and GPVI in recurrent venous thromboembolism. Thromb Res2023; 221: 58–64.
52.
RobertsLNPatelRKGossDE, et al.Relationship between development of post-thrombotic syndrome and serial ultrasound, D-dimer, and factor VIII activity after a first deep venous thrombosis. J Vasc Surg Venous Lymphat Disord2016; 4: 28–35.
53.
PolakMWSiudutJPlensK, et al.Prothrombotic clot properties can predict venous ulcers in patients following deep vein thrombosis: a cohort study. J Thromb Thrombolysis2019; 48: 603–609.
54.
MrozinskaSCieslikJBroniatowskaE, et al.Elevated leptin and decreased adiponectin independently predict the post-thrombotic syndrome in obese and non-obese patients. Sci Rep2018; 8: 6938.
55.
SiudutJGrelaMWypasekE, et al.Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome. J Thromb Haemost2016; 14: 784–793.
56.
RabinovichACohenJMCushmanM, et al.Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome. J Thromb Haemost2015; 13: 398–408.
57.
Roumen-KlappeEMJanssenMCHVan RossumJ, et al.Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: a prospective study. J Thromb Haemost2009; 7: 582–587.
58.
SchulmanSLindmarkerPHolmströmM, et al.Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost2006; 4: 734–742.
59.
StainMSchönauerVMinarE, et al.The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost2005; 3: 2671–2676.
60.
LatellaJDesmaraisSMironM-J, et al.Relation between D-dimer level, venous valvular reflux and the development of post-thrombotic syndrome after deep vein thrombosis. J Thromb Haemost2010; 8: 2169–2175.
61.
RabinovichACohenJMPrandoniP, et al.Association between thrombophilia and the post-thrombotic syndrome: a systematic review and meta-analysis. J Thromb Haemost2014; 12: 14–23.
62.
BittarLFSilvaLQ daOrsiFL de A, et al.Increased inflammation and endothelial markers in patients with late severe post-thrombotic syndrome. PLoS One2020; 15: e0227150.
63.
BoumanACMcPhersonHCheungYW, et al.Clot structure and fibrinolytic potential in patients with post thrombotic syndrome. Thromb Res2016; 137: 85–91.
64.
KremersBMMBirocchiSvan OerleR, et al.Searching for a common thrombo-inflammatory basis in patients with deep vein thrombosis or peripheral artery disease. Front Cardiovasc Med2019; 6: 33.
65.
MazettoBMOrsiFLASilveiraSAF, et al.Severe postthrombotic syndrome is associated with characteristic sonographic pattern of the residual thrombosis. Blood Coagul Fibrinolysis2016; 27: 673–678.
66.
SpieziaLCampelloEGioloE, et al.Thrombophilia and the risk of post-thrombotic syndrome: retrospective cohort observation. J Thromb Haemost2010; 8: 211–213.
67.
McLeodBLimHYNandurkarH, et al.Overall hemostatic potential assay detects risk of progression to post-thrombotic syndrome in anticoagulated patients following deep vein thrombosis. Diagnostics (Basel)2022; 12: 3165.
68.
KahnSRDesmaraisSDucruetT, et al.Comparison of the villalta and ginsberg clinical scales to diagnose the post-thrombotic syndrome: correlation with patient-reported disease burden and venous valvular reflux. J Thromb Haemost2006; 4: 907–908.
69.
SchaferKGoldschmidtEOostraD, et al.The clinical significance of ultra-high D-dimer levels. J Vasc Surg Venous Lymphat Disord2022; 10: 8–13.
70.
KosterTBlannADBriëtE, et al.Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet1995; 345: 152–155.
71.
MichelsALillicrapDYacobM. Role of von Willebrand factor in venous thromboembolic disease. JVS Vasc Sci2021; 3: 17–29.
72.
RietveldIMLijferingWMle CessieS, et al.High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von willebrand factor. J Thromb Haemost2019; 17: 99–109.
73.
EdvardsenMSHindbergKHansenE-S, et al.Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism. Blood Adv2021; 5: 224–232.
74.
López-AzkarretaIReusSMarcoP, et al.[Prospective study of the risk factors for the development of post-thrombotic syndrome after proximal deep venous thrombosis]. Med Clin (Barc)2005; 125: 1–4.
75.
OrdiJSalmerónLAcostaF, et al.[Study of prognostic factors and prevalence of post-thrombotic syndrome in patients with deep vein thrombosis in Spain]. Med Clin (Barc)2016; 146: 49–54.
76.
BellmuntSGonzález-CañasEValldauraT, et al.What awaits the patient following a diagnosis of deep vein thrombosis? A study of the factors predicting mortality, post-thrombotic syndrome and quality of life. Angiologia2006; 58: 39–49.
77.
EngesethMEndenTSandsetPM, et al.Limitations of the villalta scale in diagnosing post-thrombotic syndrome. Thrombosis Research2019; 184: 62–66.
78.
WikHSGhanimaWSandsetPM, et al.Scoring systems for postthrombotic syndrome. Semin Thromb Hemost2017; 43: 500–504.
79.
Van der VeldenSKShadidNHNelemansPJ, et al.How specific are venous symptoms for diagnosis of chronic venous disease?Phlebology2014; 29: 580–586.
80.
GalanaudJ-PHolcroftCARodgerMA, et al.Comparison of the Villalta post-thrombotic syndrome score in the ipsilateral vs. contralateral leg after a first unprovoked deep vein thrombosis. J Thromb Haemost2012; 10: 1036–1042.
81.
ChernyshINNagaswamiCKosolapovaS, et al.The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli. Sci Rep2020; 10: 5112.
82.
PérezLMPareja-GaleanoHSanchis-GomarF, et al.‘Adipaging’: ageing and obesity share biological hallmarks related to a dysfunctional adipose tissue. J Physiol2016; 594: 3187–3207.
83.
van DielenFMvan’t VeerCScholsAM, et al.Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord2001; 25: 1759–1766.
84.
AguirreLNapoliNWatersD, et al.Increasing adiposity is associated with higher adipokine levels and lower bone mineral density in obese older adults. J Clin Endocrinol Metab2014; 99: 3290–3297.
85.
LiskoITiainenKStenholmS, et al.Inflammation, adiposity, and mortality in the oldest old. Rejuvenation Res2012; 15: 445–452.
86.
MargaglioneMCappucciGd’AddeddaM, et al.PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology1998; 18: 562–567.
87.
HagerKPlattD. Fibrin degeneration product concentrations (D-dimers) in the course of ageing. Gerontology1995; 41: 159–165.
88.
PerrierADesmaraisSGoehringC, et al.D-dimer testing for suspected pulmonary embolism in outpatients. Am J Respir Crit Care Med1997; 156: 492–496.
89.
TardyBTardy-PoncetBViallonA, et al.Evaluation of D-dimer ELISA test in elderly patients with suspected pulmonary embolism. Thromb Haemost1998; 79: 38–41.
90.
RighiniMGoehringCBounameauxH, et al.Effects of age on the performance of common diagnostic tests for pulmonary embolism. Am J Med2000; 109: 357–361.
91.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021; 372: n71.
